CRISPR used in human trials for first time in U.S.

Do scientists know enough about gene editing to move forward with human trials?

  • Doctors used the gene-editing tool in an attempt to treat a 34-year-old patient with sickle cell disease.
  • Last year, a Chinese scientist caused major controversy when he used CRISPR to genetically edit two human embryos.
  • It's unclear exactly what risks are involved in gene editing.


For the first time in the U.S., doctors used the gene-editing tool CRISPR to alter the genes of a human.

The patient was Victoria Gray, 34, who suffers from sickle cell disease, a genetic defect in which bone marrow produces a defective protein that renders blood cells unable to carry oxygen effectively.

"It's horrible," Gray told NPR. "When you can't walk or lift up a spoon to feed yourself, it gets real hard."

In an experimental procedure, doctors took stem cells from Gray's own bone marrow and used CRISPR to disable the faulty gene — named BCL11A. This disabling boosts the production of fetal hemoglobin, an oxygen transport protein. All humans produce fetal hemoglobin when young, and for decades it's been thought that this protein, in particular, helps treat sickle cell disease.

Now, researchers are able to put that theory to the test.

"It's exciting to see that we might be on the cusp of a highly effective therapy for patients with sickle cell," Dr. David Altshuler, executive vice president, global research and chief scientific officer at Vertex Pharmaceuticals, which is conducting a study with CRISPR Therapeutics, told NPR. "People with sickle cell disease have been waiting a long time for therapies that just let them live a normal life."

Still, it's unclear what risks gene editing poses to humans, given that almost all past experiments have been limited to animals and culture dishes. One major risk factor has to do with the interconnectedness of genes and their unmapped functions. For example, in June, a paper published in Nature Medicine described how editing genes to yield one specific benefit might result in a number of unforeseen consequences.

Why CRISPR Gene Editing Gives Its Creator Nightmares

Specifically, the researchers of the new study were examining the potential consequences of a highly controversial gene-editing procedure conducted last year by a Chinese scientist named He Jiankui, who used CRISPR to edit two human embryos, giving them a genetic mutation that theoretically rendered them unable to contract HIV. The scientists' main takeaway? Their research suggests that people born with that specific mutation tend to die sooner than those who don't.

"There might be a public perception that one mutation does one thing, but biology doesn't work like that," Rasmus Nielsen, an evolutionary biologist who coauthored the paper with one of his postdocs, Xinzhu Wei, told Wired. "I hope this raises awareness that before we think about modifying the human genome with CRISPR, we carefully consider all the possible effects of the mutations that we create."

Still, for people with life-shortening diseases like sickle cell, the risks of gene editing might be well worth it.

"This gives me hope if it gives me nothing else," Gray told NPR. It will likely take years of further testing before gene-editing procedures could become available to a wider pool of sickle cell patients.

Biohacking: Why I'll live to be 180 years old

From computer hacking to biohacking, Dave Asprey has embarked on a quest to reverse the aging process.

Videos
  • As a teenager, founder of Bulletproof, Dave Asprey, began experiencing health issues that typically plague older adults.
  • After surrounding himself with anti-aging researchers and scientists, he discovered the tools of biohacking could dramatically change his life and improve his health.
  • He's now confident he'll live to at least 180 years old. "It turns out that those tools that make older people young make younger people kick ass," he says.
Keep reading Show less

First solar roadway in France turned out to be a 'total disaster'

French newspapers report that the trial hasn't lived up to expectations.

Image source: Charly Triballeau / AFP / Getty Images
Technology & Innovation
  • The French government initially invested in a rural solar roadway in 2016.
  • French newspapers report that the trial hasn't lived up to expectations.
  • Solar panel "paved" roadways are proving to be inefficient and too expensive.
Keep reading Show less

European wind farms could meet global energy demand, researchers now say

A new study estimated the untapped potential of wind energy across Europe.

Pixabay
Surprising Science
  • A new report calculated how much electricity Europe could generate if it built onshore wind farms on all of its exploitable land.
  • The results indicated that European onshore wind farms could supply the whole world with electricity from now until 2050.
  • Wind farms come with a few complications, but the researchers noted that their study was meant to highlight the untapped potential of the renewable energy source in Europe.
Keep reading Show less